BR112012017800A8 - Composição anestésica ou sedativa - Google Patents

Composição anestésica ou sedativa

Info

Publication number
BR112012017800A8
BR112012017800A8 BR112012017800A BR112012017800A BR112012017800A8 BR 112012017800 A8 BR112012017800 A8 BR 112012017800A8 BR 112012017800 A BR112012017800 A BR 112012017800A BR 112012017800 A BR112012017800 A BR 112012017800A BR 112012017800 A8 BR112012017800 A8 BR 112012017800A8
Authority
BR
Brazil
Prior art keywords
anesthetic
composition
sedation
sedative
individual
Prior art date
Application number
BR112012017800A
Other languages
English (en)
Other versions
BR112012017800A2 (pt
BR112012017800B1 (pt
Inventor
Marguerite Goodchild Juliet
Stanley Goodchild Colin
James Boyd Benjamin
Original Assignee
Goodchild Investiments Pty Ltd
Drawbridge Pharmaceuticals Pty Ltd
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goodchild Investiments Pty Ltd, Drawbridge Pharmaceuticals Pty Ltd, Univ Monash filed Critical Goodchild Investiments Pty Ltd
Publication of BR112012017800A2 publication Critical patent/BR112012017800A2/pt
Publication of BR112012017800A8 publication Critical patent/BR112012017800A8/pt
Publication of BR112012017800B1 publication Critical patent/BR112012017800B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÃO HOSPEDEIRA/HÓSPEDE DE ENTREGA DE SEDATIVO OU ANESTÉSICO, COMPOSIÇÃO ANESTÉSICA OU SEDATIVA, COMPOSIÇÃO ANESTÉSICA OU DE SEDAÇÃO, MÉTODO DE INDUÇÃO OU MANUTENÇÃO POR ADMINISTRAÇÃO DE BOLO INTERMITENTE OU INFUSÃO, ANESTESIA OU SEDAÇÃO EM UM INDIVÍDUO, USO DE ANESTÉSICO ESTEROIDE NEUROATIVO E CICLODEXTRINA OU UMA FORMA MODIFICADA DOS MESMOS NA FABRICAÇÃO DE UM MEDICAMENTO PARA INDUZIR ANESTESIA EM UM INDIVÍDUO E MÉTODO DE INDUÇÃO OU MANUTENÇÃO POR ADMINISTRAÇÃO DE BOLO INTERMITENTE OU INFUSÃO, SEDAÇÃO EM UM INDIVÍDUO HUMANO. A presente invenção refere-se, geralmente, ao campo de sistemas de entrega de fármaco para agentes anestésicos esteroides neuroativos. Mais particularmente, formulações anestésicas e sedativas são fornecidas na forma de preparações hospedeiras/hóspedes que compreendem um ou mais anestésicos esteroides neuroativos e uma ciclodextrina. Ciclodextrinas particulares contempladas incluem sulfoalquil éter ciclodextrinas e formas modificadas das mesmas.
BR112012017800-8A 2010-01-21 2011-01-19 composição anestésica ou sedativa BR112012017800B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (3)

Publication Number Publication Date
BR112012017800A2 BR112012017800A2 (pt) 2018-07-10
BR112012017800A8 true BR112012017800A8 (pt) 2018-08-14
BR112012017800B1 BR112012017800B1 (pt) 2020-12-08

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017800-8A BR112012017800B1 (pt) 2010-01-21 2011-01-19 composição anestésica ou sedativa

Country Status (27)

Country Link
US (2) US8697678B2 (pt)
EP (1) EP2525798B1 (pt)
JP (1) JP5930311B2 (pt)
KR (1) KR101747476B1 (pt)
CN (1) CN102802635B (pt)
AU (1) AU2011207103B2 (pt)
BR (1) BR112012017800B1 (pt)
CA (1) CA2786762C (pt)
CL (1) CL2012002032A1 (pt)
CY (1) CY1119947T1 (pt)
DK (1) DK2525798T3 (pt)
ES (1) ES2646829T3 (pt)
GB (2) GB2484244B (pt)
HK (1) HK1169031A1 (pt)
HR (1) HRP20171699T1 (pt)
HU (1) HUE035441T2 (pt)
LT (1) LT2525798T (pt)
NO (1) NO2525798T3 (pt)
NZ (1) NZ601255A (pt)
PL (1) PL2525798T3 (pt)
PT (1) PT2525798T (pt)
RS (1) RS56576B1 (pt)
RU (1) RU2574022C2 (pt)
SG (1) SG181997A1 (pt)
SI (1) SI2525798T1 (pt)
WO (1) WO2011088503A1 (pt)
ZA (1) ZA201205370B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101405545B1 (ko) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2852716C (en) * 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
LT2806877T (lt) * 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2916846A4 (en) * 2012-11-09 2016-08-10 Goodchild Invest Pty Ltd NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION
EP2925327B1 (en) * 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
EP3253418A1 (en) * 2015-02-06 2017-12-13 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
JP2018530585A (ja) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
JP7443358B2 (ja) * 2018-07-03 2024-03-05 ドローブリッジ ファーマシューティカルズ ピーティーワイ リミテッド 神経活性ステロイドおよび調製の方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP2022514991A (ja) * 2018-12-10 2022-02-16 ハロー・サイエンス・エル・エル・シー 安定な麻酔薬製剤および関連する剤形
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062359T3 (es) * 1989-05-24 1994-12-16 Innovet Inc Un procedimiento de preparacion de una composicion anestesica o hipnotica esteroidal hipoalergenica.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
KR101405545B1 (ko) * 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도

Also Published As

Publication number Publication date
KR20120136347A (ko) 2012-12-18
EP2525798A1 (en) 2012-11-28
GB201201842D0 (en) 2012-03-21
GB201210657D0 (en) 2012-08-01
HRP20171699T1 (hr) 2018-01-26
BR112012017800A2 (pt) 2018-07-10
GB2484244B (en) 2012-10-31
CN102802635A (zh) 2012-11-28
CA2786762A1 (en) 2011-07-28
WO2011088503A1 (en) 2011-07-28
CY1119947T1 (el) 2018-12-12
RU2574022C2 (ru) 2016-01-27
ES2646829T3 (es) 2017-12-18
SI2525798T1 (en) 2018-01-31
NZ601255A (en) 2013-09-27
GB2491491A (en) 2012-12-05
HUE035441T2 (en) 2018-05-02
KR101747476B1 (ko) 2017-06-14
HK1169031A1 (en) 2013-01-18
RS56576B1 (sr) 2018-02-28
GB2491491B (en) 2014-07-30
RU2012134321A (ru) 2014-02-27
US8697678B2 (en) 2014-04-15
AU2011207103B2 (en) 2013-03-21
CL2012002032A1 (es) 2012-12-21
US20120316146A1 (en) 2012-12-13
EP2525798B1 (en) 2017-08-09
AU2011207103A1 (en) 2012-07-26
US20140066417A1 (en) 2014-03-06
SG181997A1 (en) 2012-08-30
ZA201205370B (en) 2013-09-25
GB2484244A (en) 2012-04-04
LT2525798T (lt) 2018-01-10
JP5930311B2 (ja) 2016-06-08
BR112012017800B1 (pt) 2020-12-08
DK2525798T3 (da) 2017-11-20
JP2013517299A (ja) 2013-05-16
EP2525798A4 (en) 2014-02-19
NO2525798T3 (pt) 2018-01-06
PL2525798T3 (pl) 2018-05-30
US8975245B2 (en) 2015-03-10
PT2525798T (pt) 2017-11-15
CA2786762C (en) 2017-12-05
CN102802635B (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
BR112012017800A8 (pt) Composição anestésica ou sedativa
BR112014027681A2 (pt) preparações de agentes terapêuticos hidrofóbicos, métodos de fabricação e uso dos mesmos
BR112013026308A2 (pt) Compostos de benzeno substituídos
BR112014018110A8 (pt) Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
UA109785C2 (uk) Композиція фармацевтичного аерозолю, яка включає аналог вітаміну d і кортикостероїд
BR112013001299A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de diabetes e doenças correlatas em paciente humano
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
BR112014001875A2 (pt) sistema e método personalizáveis para anestesiar membrana timpânica
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
BR112012023407A2 (pt) composição em pó farmacêutica para instalação, e, processo para a preparação da mesma.
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112014008609A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, método para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
BR112015027631A2 (pt) Métodos para melhorar perfis de lipídeo usando atrasentana
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
BR112016000092A2 (pt) nanopartículas lipídicas para a cicatrização de feridas
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU)

B25G Requested change of headquarter approved

Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2011, OBSERVADAS AS CONDICOES LEGAIS.